β-Amyloid Protein Immunoreactivity in Skin Is Not a Reliable Marker of Alzheimer's Disease

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications

“…Similarly, Aβ generated from precursors released from platelets might be the source of its accumulation in mouse skin, as it was found to be concentrated around blood vessels after experimental thrombosis ( 40 ). A similar accumulation of Aβ around blood vessels in the skin of AD patients and generally in older patients was described many years ago ( 66 , 139 ). Moreover, we recently reported that Aβ immunofluorescence accumulated on blood vessel walls in the damaged part of the brain and on nearby astrocytes after middle cerebral artery occlusion ( 35 ).…”

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications

“…Similarly, Aβ generated from precursors released from platelets might be the source of its accumulation in mouse skin, as it was found to be concentrated around blood vessels after experimental thrombosis ( 40 ). A similar accumulation of Aβ around blood vessels in the skin of AD patients and generally in older patients was described many years ago ( 66 , 139 ). Moreover, we recently reported that Aβ immunofluorescence accumulated on blood vessel walls in the damaged part of the brain and on nearby astrocytes after middle cerebral artery occlusion ( 35 ).…”

AβPeptide Originated from Platelets Promises New Strategy in Anti-Alzheimer’s Drug Development

“…Amyloid protein deposit immunoreactivity was described many years ago in and around the endothelium of dermal blood vessels in aged AD patients and controls and was proposed as a marker of the disease in AD patients [ 69 ]. But another study found that skin accumulation of A β around blood vessels was unrelated to the severity of symptoms in AD patients, occurring also in some healthy subjects [ 70 ]. Interestingly, A β protein was also detected in the skin of patients with amyotrophic lateral sclerosis but not in controls [ 71 ].…”

Biochemical signature in Alzheimer’s disease

“…A quick and easy test based on a biochemical marker could also minimize the cost and time it takes to diagnose a patient now. For years, researchers have looked for ante-mortem biochemical markers in different peripheral tissues and cells such as erythrocytes [12] , lymphocytes [13] , urine [14] , hair [15] and skin [16,17] . However, until now there has been no clarity on biochemical markers for AD that would allow presymptomatic detection or definitive pre-morbid diagnosis.…”

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications

“…Similarly, Aβ generated from precursors released from platelets might be the source of its accumulation in mouse skin, as it was found to be concentrated around blood vessels after experimental thrombosis ( 40 ). A similar accumulation of Aβ around blood vessels in the skin of AD patients and generally in older patients was described many years ago ( 66 , 139 ). Moreover, we recently reported that Aβ immunofluorescence accumulated on blood vessel walls in the damaged part of the brain and on nearby astrocytes after middle cerebral artery occlusion ( 35 ).…”

AβPeptide Originated from Platelets Promises New Strategy in Anti-Alzheimer’s Drug Development

“…Amyloid protein deposit immunoreactivity was described many years ago in and around the endothelium of dermal blood vessels in aged AD patients and controls and was proposed as a marker of the disease in AD patients [ 69 ]. But another study found that skin accumulation of A β around blood vessels was unrelated to the severity of symptoms in AD patients, occurring also in some healthy subjects [ 70 ]. Interestingly, A β protein was also detected in the skin of patients with amyotrophic lateral sclerosis but not in controls [ 71 ].…”

Biochemical signature in Alzheimer’s disease

“…A quick and easy test based on a biochemical marker could also minimize the cost and time it takes to diagnose a patient now. For years, researchers have looked for ante-mortem biochemical markers in different peripheral tissues and cells such as erythrocytes [12] , lymphocytes [13] , urine [14] , hair [15] and skin [16,17] . However, until now there has been no clarity on biochemical markers for AD that would allow presymptomatic detection or definitive pre-morbid diagnosis.…”

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications

“…Similarly, Aβ generated from precursors released from platelets might be the source of its accumulation in mouse skin, as it was found to be concentrated around blood vessels after experimental thrombosis ( 40 ). A similar accumulation of Aβ around blood vessels in the skin of AD patients and generally in older patients was described many years ago ( 66 , 139 ). Moreover, we recently reported that Aβ immunofluorescence accumulated on blood vessel walls in the damaged part of the brain and on nearby astrocytes after middle cerebral artery occlusion ( 35 ).…”

AβPeptide Originated from Platelets Promises New Strategy in Anti-Alzheimer’s Drug Development

“…Amyloid protein deposit immunoreactivity was described many years ago in and around the endothelium of dermal blood vessels in aged AD patients and controls and was proposed as a marker of the disease in AD patients [ 69 ]. But another study found that skin accumulation of A β around blood vessels was unrelated to the severity of symptoms in AD patients, occurring also in some healthy subjects [ 70 ]. Interestingly, A β protein was also detected in the skin of patients with amyotrophic lateral sclerosis but not in controls [ 71 ].…”

Biochemical signature in Alzheimer’s disease

“…A quick and easy test based on a biochemical marker could also minimize the cost and time it takes to diagnose a patient now. For years, researchers have looked for ante-mortem biochemical markers in different peripheral tissues and cells such as erythrocytes [12] , lymphocytes [13] , urine [14] , hair [15] and skin [16,17] . However, until now there has been no clarity on biochemical markers for AD that would allow presymptomatic detection or definitive pre-morbid diagnosis.…”